- Home
- IMNM vs DNTH Comparison
IMNM vs DNTH Comparison
Compare IMNM & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNM
- DNTH
- Stock Information
- Founded
- IMNM 2006
- DNTH 2015
- Country
- IMNM United States
- DNTH United States
- Employees
- IMNM N/A
- DNTH N/A
- Industry
- IMNM Medicinal Chemicals and Botanical Products
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- IMNM Health Care
- DNTH Health Care
- Exchange
- IMNM Nasdaq
- DNTH Nasdaq
- Market Cap
- IMNM 945.8M
- DNTH 1.0B
- IPO Year
- IMNM 2020
- DNTH N/A
- Fundamental
- Price
- IMNM $9.69
- DNTH $37.08
- Analyst Decision
- IMNM Strong Buy
- DNTH Strong Buy
- Analyst Count
- IMNM 8
- DNTH 8
- Target Price
- IMNM $24.75
- DNTH $60.67
- AVG Volume (30 Days)
- IMNM 756.6K
- DNTH 894.0K
- Earning Date
- IMNM 08-06-2025
- DNTH 11-06-2025
- Dividend Yield
- IMNM N/A
- DNTH N/A
- EPS Growth
- IMNM N/A
- DNTH N/A
- EPS
- IMNM N/A
- DNTH N/A
- Revenue
- IMNM $12,589,000.00
- DNTH $4,854,000.00
- Revenue This Year
- IMNM N/A
- DNTH N/A
- Revenue Next Year
- IMNM $154.73
- DNTH N/A
- P/E Ratio
- IMNM N/A
- DNTH N/A
- Revenue Growth
- IMNM 16.74
- DNTH 17.87
- 52 Week Low
- IMNM $5.15
- DNTH $13.37
- 52 Week High
- IMNM $16.73
- DNTH $38.59
- Technical
- Relative Strength Index (RSI)
- IMNM 48.73
- DNTH 83.10
- Support Level
- IMNM $8.67
- DNTH $22.81
- Resistance Level
- IMNM $9.71
- DNTH $24.81
- Average True Range (ATR)
- IMNM 0.63
- DNTH 2.63
- MACD
- IMNM -0.04
- DNTH 1.45
- Stochastic Oscillator
- IMNM 51.64
- DNTH 90.43
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.